Larimar Therapeutics Financials - Benzinga

Larimar Therapeutics Inc

LRMRNASDAQ

Trade with Public

Trade with Public

$3.19

0.0551.75%

In chiusura: Sep 30, 5:00 PM EST

$3.19

N/A

Post-mercato: 4:26 PM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Larimar Therapeutics Financials

Larimar Therapeutics (LRMR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share

Benzinga Newsdesk

PRO
Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 42.59 percent. This is a 32.61 percent increase over losses of $(0.46) per share

Benzinga Newsdesk

Earnings Scheduled For March 19, 2026

Benzinga Insights

PRO
Larimar Therapeutics Q4 EPS $(0.73) Misses $(0.45) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.45) by 62.22 percent. This is a 62.22 percent decrease over losses of $(0.45) per share

Benzinga Newsdesk

PRO
Larimar Therapeutics Q3 EPS $(0.61) Misses $(0.40) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.40) by 51.36 percent. This is a 154.17 percent decrease over losses of $(0.24) per

Benzinga Newsdesk

PRO
Larimar Therapeutics Q2 EPS $(0.41) Beats $(0.48) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.48) by 14.76 percent. This is a 20.59 percent decrease over losses of $(0.34) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved